Trastuzumab-dendrimer-fluorine drug delivery system

• Authors: Dorota Bartusik-Aebisher
• Languages of publication: EN

Abstracts

EN

Breast cancer is the most frequently occurring cancer in women worldwide with more than one million new cases diagnosed each year. The objective of this study was to develop a Trastuzumab-dendrimer-fluorine drug delivery system by covalent attachment of Trastuzumab to a fluorinated PAMAM-G5 dendrimer. The Trastuzumab-dendrimer-fluorine drug delivery system was used to treat MCF-7 with Her-2 overexpression. The use of PAMAM-G5, which bears 128 primary amine surface groups, enables covalent attachment of both antibody and fluorinated functional groups for enhancement of cellular uptake. Thus, Trastuzumab was covalently attached to fluorinated PAMAM-G5 dendrimers and used as a vehicle for drug delivery to three dimensional (3D) cultured cells. The efficiency of Trastuzumab-dendrimer-fluorine drug delivery system binding to Her-2 receptors was measured by cell viability. The Trastuzumab-dendrimer-fluorine drug delivery system was found to have a higher efficiency in the treatment of Her-2 overexpressing MCF-7 cells than Trastuzumab alone. The incorporation of 19F by addition of heptafluorobutyric acid anhydride (HFAA) to PAMAM-G5 increased lipophilicity and hydrophobicity of drug delivery system.

Keywords

EN

trastuzumab; Dendrimer; Drug delivery system; Her-2 receptor

• Journal: Acta Poloniae Pharmaceutica - Drug Research
• Year: 2020
• Volume: 77
• Issue: 2
• Pages: 331-341

Dates

published

2020-04-29

Contributors

author

Dorota Bartusik-Aebisher

Identifiers

DOI

10.32383/appdr/118740